The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
Figure 5
ISC-4 and cetuximab cooperatively reduce phospho-Akt.
(A) Western blot analysis of RKO cells treated with ISC-4 (2 µM) and cetuximab (1 µg/mL) alone or in combination for 24 hours. Densitometry of phospho-Akt levels are shown above the blot as normalized to Ran as relative to control treatment. (B) Western blot analysis of RKO cells treated with ISC-4 (2 µM) and cetuximab (1 µg/mL) alone or in combination for indicated time periods. Ran is shown as a loading control. (C) Western blot analysis of indicated human colon cancer cell lines following treatment with the combination (Rx) of ISC-4 (2 µM) and cetuximab (1 µg/mL) for 8 hrs. *P<0.05 compared to control.